Literature DB >> 7656507

Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs.

G V Milton1, M W Jann.   

Abstract

Psychotic symptoms related to mental and medical disorders can pose a medical emergency. Selecting an appropriate antipsychotic medication to treat this emergency is based on the clinical situation, preferred route of administration, pharmacokinetic profile of the antipsychotic and the medications currently being taken by the patient. Intramuscular preparations are usually preferred over oral medication when the patients are not co-operative and require drugs with a faster onset of action and good bioavailability. High potency antipsychotics such as haloperidol and fluphenazine are effective in stabilising patients with psychotic symptoms quickly. Loxapine is an alternative when sedation is necessary and molindone is useful if a short-acting antipsychotic is required. Rapid neuroleptisation with intramuscular preparations of antipsychotic achieves therapeutic drug concentrations more rapidly, and also provides optimal control of psychotic symptoms. If the patient is cooperative, liquid oral preparations can be used; they are as effective as intramuscular formulations. If long term treatment with an antipsychotic in necessary and patients are stabilised, they can be switched from intramuscular to oral preparations. The oral dose is usually 1.5 to 5 times the total intramuscular dose per day, based on the bioavailability of the antipsychotic medication. If the patient is currently taking antipsychotic medication when the emergency situation occurs, it is usually adequate to increase the dose of antipsychotic drug. Appropriate dose adjustment or antipsychotic selection is necessary when drug interactions are expected. An in-depth knowledge of the pharmacokinetic profile and drug interaction profile of antipsychotic in necessary for the selection of the appropriate antipsychotic for any given emergency situation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7656507     DOI: 10.2165/00003088-199528060-00007

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  71 in total

1.  Rapid tranquilization: a comparison of thiothixene with loxapine.

Authors:  W R Dubin; K J Weiss
Journal:  J Clin Psychiatry       Date:  1986-06       Impact factor: 4.384

2.  Drug-induced illness leading to hospitalization.

Authors:  G J Caranasos; R B Stewart; L E Cluff
Journal:  JAMA       Date:  1974-05-06       Impact factor: 56.272

3.  Effects of carbamazepine on plasma haloperidol levels.

Authors:  M W Jann; L Ereshefsky; S R Saklad; D R Seidel; C M Davis; N R Burch; C L Bowden
Journal:  J Clin Psychopharmacol       Date:  1985-04       Impact factor: 3.153

4.  The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.

Authors:  V Khot; C L DeVane; E R Korpi; D Venable; L B Bigelow; R J Wyatt; D G Kirch
Journal:  J Clin Psychopharmacol       Date:  1993-04       Impact factor: 3.153

5.  Therapeutic blood levels of fluphenazine: plasma or RBC determinations?

Authors:  M L Mavroidis; D R Kanter; J Hirschowitz; D L Garver
Journal:  Psychopharmacol Bull       Date:  1984

6.  Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.

Authors:  M W Jann; S R Saklad; L Ereshefsky; A L Richards; C A Harrington; C M Davis
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

7.  A pharmacokinetic study of trifluoperazine in two ethnic populations.

Authors:  K K Midha; E M Hawes; J W Hubbard; E D Korchinski; G McKay
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients.

Authors:  B A Stotsky
Journal:  Dis Nerv Syst       Date:  1977-12

9.  Fluphenazine pharmacokinetics and therapeutic response.

Authors:  M W Dysken; J I Javaid; S S Chang; C Schaffer; A Shahid; J M Davis
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels.

Authors:  L Rivera-Calimlim; H Nasrallah; J Strauss; L Lasagna
Journal:  Am J Psychiatry       Date:  1976-06       Impact factor: 18.112

View more
  2 in total

Review 1.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 2.  Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.

Authors:  A Cario Altamura; Francesca Sassella; Annalisa Santini; Clauno Montresor; Sara Fumagalli; Emanuela Mundo
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.